US EditionFormer Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee
- Mikael Dolsten joined Formation Bio as a strategic advisor, as announced on April 2, 2025, in New York.
- Formation Bio, an AI-driven pharmaceutical firm, sought Dolsten's expertise to enhance its drug development strategies.
- Dolsten, previously Pfizer's Chief Scientific Officer, will guide asset selection and provide strategic direction on AI initiatives.
- Dolsten noted AI's shift to a core driver of efficiency in pharmaceutical development; he stated that development remains a bottleneck.
- Formation Bio aims to expand its pipeline using AI, hoping Dolsten's guidance will accelerate drug development and market delivery.
Insights by Ground AI
Does this summary seem wrong?
48 Articles
48 Articles
All
Left
4
Center
14
Right
4
Rutland Herald+47 Reposted by 47 other sources
Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee
NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development, today announced that Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President, Pfizer Research & Development, has joined the company as a strategic…
Coverage Details
Total News Sources48
Leaning Left4Leaning Right4Center14Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 18%
C 64%
R 18%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
